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Abstract: The mycotoxin, ochratoxin A (OTA), is thought to be responsible for Balkan 
endemic nephropathy. OTA accumulates in several tissues, especially in the kidneys and 
liver.  The  excretion  of  OTA  into  urine  is  thought  to  be  mainly  by  tubular  secretion, 
presumably  via  the  organic  anion  transport  system.  Recently,  several  families  of 
multispecific organic anion transporters have been identified: organic anion transporters 
(OATs),  organic  anion-transporting  polypeptides  (OATPs),  oligopeptide  transporters 
(PEPTs), and ATP-binding cassette (ABC) transporters, such as MRP2 and BCRP. These 
renal transporters mediate the transmembrane transport of OTA and play a pivotal role in 
the development of OTA-induced nephrotoxicity. 
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1. Introduction 
Ochratoxin  A  (OTA),  a  structural  analog  of  phenylalanine  that  contains  a  chlorinated 
dihydroisocoumarin moiety [1], is a mycotoxin produced as a secondary metabolite in different species 
of Aspergillus ochraceus and Penicillium verrucosum [2]. OTA  may  be distributed extensively in 
agricultural  commodities  and  in  the  natural  environment  [3].  Contamination  of  foods  with  OTA, 
particularly of cereals, nuts, and coffee beans, has been noted in Eastern and Central Europe, North 
Africa, North America, and Japan [4]. Recently, OTA has received considerable attention because of 
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its deleterious effects on human and animal health [5–7]. OTA accumulates in several tissues in the 
body, with the kidney being its main target, where it exerts toxic and carcinogenic effects [8,9]. Three 
forms of human renal disease, Balkan endemic nephropathy (BEN), chronic interstitial nephritis, and 
karyomegalic  interstitial  nephritis,  appear  to  be  caused,  at  least  in  part,  by  enhanced  exposure  to  
OTA [10]. However, the pathophysiological role of OTA in human renal disease has not yet been  
completely determined. 
In the kidney, OTA mainly impairs proximal tubular functions and causes glucosuria, enzymuria, 
and a decrease in the transport of para-aminohippuric acid (PAH), a prototypical renal organic anion 
[11–13]. An in vivo study revealed that probenecid, a typical inhibitor of organic anion transporters 
(OATs),  inhibited  the  renal  clearance  of  OTA  [14].  In  addition,  glomerular  filtration  of  OTA  is 
considered to be minimal, since more than 99% of OTA is bound to plasma proteins [15,16]. From 
these results, it is thought that the excretion of OTA into the urine is mainly by tubular secretion, 
presumably via the OAT system, and that this may play an important role in OTA accumulation and in 
the development of nephrotoxicity. Thus, knowledge of the fate of OTA that has reached the tubular 
lumen for its elimination is of crucial importance to understanding how OTA accumulates in renal 
tubular cells, and for developing possible strategies for prevention of OTA-induced nephrotoxicity. 
In this review, we first summarize the findings from classical transport studies of OTA. Second, we 
briefly introduce the molecular identification of renal organic anion transporters. Third, we describe, 
by  cloned  OATs,  the  OTA  transport  properties.  Through  the  text,  we  discuss  the  current  idea 
implicating the function of  the renal organic anion transporters as a determinant of OTA-induced 
nephrotoxicity. For further information concerning the roles of OTA as a signal modulator in the 
kidney, please refer to a precise review [17]. 
2. OTA Transport Systems in Classical Studies 
Before the molecular identification of renal OATs, there were several lines of evidence that showed 
transcellular transport of OTA occurred via carriers (transporters).  
2.1. Renal Slice Study 
In 1979, Berndt and Hayes [18] found that daily administration of OTA in rats caused altered renal 
slice transport of several organic compounds. In addition, there was persistent urinary hypoosmolality 
coupled with excessive glucose and protein excretion. They also examined the direct addition of OTA 
to fresh renal cortex slices and observed depressed transport of some organic compounds. Based on 
these findings, they concluded that OTA has the capacity to produce alterations in renal function that 
are suggestive of nephrotoxicity. 
Friis et al. [19] also found, by using pig renal cortical slices, that OTA enters proximal tubular cells 
by the common organic anion transport system for PAH and phenolsulphophthalein (PSP). 
2.2. Membrane Vesicle Study 
In 1988, Sokol et al. [20] examined that the effect of OTA on the transport of [
3H]PAH in brush 
border  membrane  vesicles  (BBMV)  and  in  basolateral  membrane  vesicles  (BLMV)  from  canine 
kidneys. OTA was as effective an inhibitor of PAH uptake, in both membranes, as probenecid. Based Toxins 2010, 2                            
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on the finding that OTA produced trans-stimulation of PAH transport in both BBMV and BLMV, they 
concluded  that  OTA  is  transported  across  both  of  these  membranes  via  the  renal  organic  anion 
transport system.  
2.3. Micropuncture Study 
In 1997, Zingerle et al. [21] micropunctured in situ the superficial early proximal and early distal 
tubules of male Wistar rats and showed, after microinfusion of OTA into superficial nephrons, that 
OTA was reabsorbed in the proximal as well as the distal parts of the nephron. They also reported that: 
(1)  one-third  of  reabsorption  takes  place  in  the  distal  tubule  or  the  collecting  duct,  or  both,  and  
two-thirds  take  place  in  the  proximal  tubule;  (2)  "distal"  reabsorption  can  be  explained,  at  least 
partially,  by  nonionic  diffusion;  (3)  "proximal"  reabsorption  was  partially  mediated  by  the  
H
+-dipeptide cotransporter and (4) reabsorption of filtered and secreted OTA delay its excretion and 
may lead to accumulation of the toxin in the renal tissue.  
2.4. Tubular Suspension Study 
Groves’s  group [22] examined the  transport of OTA across  the renal peritubular  membrane  in 
suspensions of rabbit renal proximal tubules. OTA transport across the peritubular membrane was a 
high-affinity, low-capacity carrier-mediated process with a Km value of 1.4 µ M. The apparent Ki value 
for [
3H]PAH uptake by OTA inhibition was 1.5 µ M, which is similar to the Km value for OTA uptake 
in tubule suspensions, and suggests that OTA could be a substrate for the organic anion pathway. The 
capacity and affinity for peritubular OTA transport were 40-fold lower and more than 100-fold greater, 
respectively,  than  those  measured  for  the  peritubular  uptake  of  [
3H]PAH  in  tubule  suspensions. 
Probenecid-sensitive, PAH-insensitive uptake of OTA suggested that at least one mediated pathway, 
other than the organic anion transporter, was involved in the peritubular uptake of OTA. The ability of 
octanoic acid to inhibit OTA transport to the same extent as probenecid, and to a greater extent than 
PAH, suggests that a separate fatty acid transport pathway may be involved in the accumulation of 
OTA in suspensions of rabbit renal proximal tubules. 
2.5. Isolated Tubular Study 
Groves et al. [23] studied the transepithelial transport of OTA using primary cultures of rabbit renal 
proximal  tubule  cells  grown  under  improved  culture  conditions.  The  basal-to-apical  (B-to-A) 
transepithelial  flux,  i.e.,  secretion,  of  this  fluorescent  organic  acid  was  measured  in  the  primary 
cultures of rabbit renal proximal tubule cells. The B-to-A flux of OTA increased with time and reached 
a steady state after 12 h. On the other hand, the A-to-B flux, i.e., reabsorption, of OTA was minimal 
over time. The secretory flux of OTA was as much as eight-fold greater than the reabsorptive flux, 
indicating that a net secretion is the primary mechanism for OTA clearance by the proximal tubule. 
The high affinity measured for the B-to-A flux of OTA suggests that at concentrations typical of 
naturally  occurring  exposures,  transepithelial  secretion  by  the  organic  anion  transport  pathway 
represents a significant avenue for excretion of this mycotoxin by the renal proximal tubule. Toxins 2010, 2                            
 
 
1384 
2.6. Cell Monolayer Study 
Schwerdt et al. [24] investigated the transepithelial transport of OTA across monolayers of two 
collecting duct-derived cell clones (Madin-Darby canine kidney cells (MDCK)-C7 and MDCK-C11 
cells, resembling principal and intercalated cells, respectively), either from the apical to the basolateral 
side, or vice versa, on permeable supports. They showed that OTA is transported across the apical 
membrane of MDCK cells by both non-ionic diffusion and by an H
+-dipeptide cotransporter, and 
concluded that the reabsorption of OTA in the collecting duct contributes to the observed long half-life 
of OTA in the mammalian body.  
Then, Schwerdt et al. [25] studied, in detail, the characteristics of apical uptake of [
3H]OTA in 
MDCK-C11 cells. They showed that apical uptake of OTA occurs by a Na
+-independent transport. The 
uptake is mediated partly by H
+-dipeptide cotransport (30%), partly by organic anion transporter (20%), 
and partly by diffusion (20%). The remaining part occurs by as-yet-unidentified, but pH-dependent 
transport mechanisms. Acidic urine in distal parts of the nephron thus provides the main risk for the 
OTA uptake that leads to its reabsorption. Thus, alkalinization of the urine should help prevent this 
reabsorption. Bahnemann et al. [26] investigated the kinetics of secretion and the extent of urine and 
tissue accumulation in situ by using a non-filtering amphibian kidney model. They demonstrated that 
transepithelial secretion is an effective way of accumulating OTA in the tubular lumen, and thus, of 
promoting OTA’s urinary excretion. Basolateral transport, via the organic anion carrier and an amino 
acid carrier, involves the active steps of transepithelial secretion. Luminal exit of OTA is a passive 
process. Furthermore, tissue accumulation by basolateral active transport supports the toxic action of 
OTA on proximal tubular cells.  
Next,  Sauvant  et  al.  [27]  investigated  the  effect  of  OTA  on  proximal  tubule-derived  opossum 
kidney (OK) cells, because a decline in the net secretion of PAH was observed after chronic exposure 
to OTA in vivo. They found that long-term incubation with free OTA in the nanomolar range reduces 
the activity of the organic anion transporter without influencing general cell function, and that OTA 
seems to act preferentially on organic anion transport, by affecting the exchange of organic anions and 
dicarboxylates. This effect leads to the reduction of its own secretion. 
Welborn et al. [28] studied the peritubular transport of fluorescent OTA into single proximal tubule 
segments of the rabbit by using epifluorescence microscopy. Initial rates of OTA uptake into the S2 
segments  were  saturable  and  adequately  described  by  Michaelis-Menten  kinetics  (Km:  2.2  µ M). 
Several lines of evidence indicated that peritubular uptake of OTA in S2 segments was effectively 
limited to the “classical” organic anion transporter. The high affinity and relatively high capacity of 
this pathway for OTA suggests that the peritubular uptake may be a significant avenue for the entry of 
this toxin into proximal tubule cells. 
Figure 1 depicts the summary of the classical concept for OTA transport systems in the kidneys. 
Tubular secretion of OTA is mainly performed by the organic anion transport system in the proximal 
tubules  and  secreted  OTA  was  reabsorbed  in  the  proximal  tubules,  distal  tubules  (TAL),  and  the 
collecting ducts (CCD) by several transport systems, leading to the delay of OTA excretion and the 
accumulation of OTA in tubular cells. Toxins 2010, 2                            
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Figure 1. Transport systems for OTA along the nephron. OTA secretion is performed by 
the  proximal  tubular  organic  anion  secretion  pathway.  OTA  is  reabsorbed  along  the 
nephron from apical side. Abbreviations, PT: proximal tubules, TAL: thick ascending limb 
of the loop of Henle, CD: collecting duct. 
 
3. Molecular Identities of Renal Organic Anion Transporters 
In this section, we will briefly introduce the renal transporters for organic anionic drugs. A number 
of reviews [29–34] on organic anion transporters are available. Figure 2 shows cloned organic anion 
transporters of renal proximal tubules that have been reported to date. 
Figure  2.  Proposed  model  of  organic  anion  transporters  in  renal  proximal  tubules. 
Abbreviations,  OAs:  organic  anions,  DCs:  dicarboxylates,  MCs:  monocarboxylates,  
GSH: glutathione. 
 Toxins 2010, 2                            
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3.1. Organic Anion Transporter (OAT) Family SLC22 
OAT1: Rat Oat1 mRNA is expressed predominantly in the kidneys and weakly in the brain [35]. In 
the  kidneys,  OAT1  protein  is  localized  in  the  basolateral  membrane  of  proximal  tubular  cells.  
OAT1-mediated  uptake  of  PAH  is  stimulated  by  an  outwardly  directed  concentration  gradient  of 
dicarboxylates, such as α-ketoglutarate. The substrate selectivity of OAT1 is markedly broad. These 
substrates  include  endogenous  substances,  such  as  dicarboxylates,  cyclic  nucleotides,  and 
prostaglandins,  and  exogenous  substances,  such  as  various  anionic  drugs  and  environmental 
compounds [36]. 
OAT2: Oat2 was originally isolated from the rat liver as a novel liver-specific transport protein 
with an unknown function [37]. OAT2 is expressed predominantly in the liver and weakly in the 
kidneys.  The  typical  substrates  of  OAT2  are  salicylate,  acetylsalicylate,  prostaglandin  E2  (PGE2), 
dicarboxylates, PAH, zidovudine (AZT), and tetracycline [31]. 
OAT3: Oat3 was initially isolated from the rat brain [38]. OAT3 mRNA is expressed in the kidneys 
and the brain. In the kidneys, OAT3 is localized in the basolateral membrane of proximal tubular cells. 
Like OAT1, OAT3 recognizes a broad spectrum of substrates. It mediates the high affinity transport of 
PAH,  estrone  sulfate  (ES),  OTA,  and  various  drugs,  including  the  cationic  drug  cimetidine,  in 
exchange for dicarboxylates inside cells [31]. 
OAT4: OAT4 was cloned from human kidneys [39]. OAT4 mRNA is expressed in the kidneys and 
is localized in the apical membrane of proximal tubular cells. When expressed in Xenopus oocytes, 
OAT4 mediates the Na
+-independent, high-affinity transport of ES, dehydroepiandrosterone sulfate, 
OTA, PGE2, and PGF2α [31]. 
Oat5: Oat5 was identified from the rat kidney [40]. It is expressed exclusively in the kidneys. Rat 
Oat5 is localized in the apical side of proximal tubules. Oat5 mediates the transport of steroid sulfates, 
as well as OTA. 
Oat8: Oat8 was recently identified from the rat kidney [41]. It is expressed exclusively in the 
kidneys.  Rat  Oat8  protein  is  localized  in  the  collecting  duct.  Additionally,  it  is  colocalized  with  
V-ATPase in plasma membranes and the intracellular vesicles of various subtypes of intercalated cells. 
Like Oat5, Oat8 mediates the transport of steroid sulfates, as well as OTA. 
Oat9: Oat9 has recently been identified from the mouse kidney [42]. It is expressed in the kidneys 
and in the liver. Oat9 has two isoforms: a long form and a short form. The short form of Oat9 (Oat9S) 
is functional and mediates the transport of zwitterion L-carnitine, as well as cimetidine and salicylic 
acid. Oat9 is localized in the apical side of proximal tubules. 
OAT10: Bahn et al. showed that hORCTL3 (human organic cation transporter like 3; OCTL1), an 
orphan  transporter  expressed  mainly  in  the  kidneys,  transports  nicotinate,  PAH,  and  uric  acid.  
They  renamed  it  OAT10  [43].  They  suggested  that  OAT10  is  the  molecule  responsible  for  
cyclosporine A-induced hyperuricemia. 
3.2. Organic Anion Transporting Polypeptide (OATP) Family SLC21/SLCO 
The first member of this family, oatp1, was identified from the rat liver, by an expression cloning 
method, as a sodium-independent bile acid transporter [44]. Thus far, 11 human isoforms and 14 rat 
isoforms  have  been  identified  in  the  OATP  family  [45].  Although  some  OATPs  are  selectively Toxins 2010, 2                            
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involved in the hepatic uptake of bulky and relatively hydrophobic organic anions, most OATPs are 
expressed in many tissues, such as the blood-brain barrier, choroid plexus, lungs, heart, intestine, 
kidneys, placenta, and testes. The OATP family is divided into six sub-families (OATP1–OATP6). 
There are considerable species differences in the OATP families among rodents and humans. Among 
human OATPs, only OATP4C1 is mainly expressed in the kidneys [46]. Oatp1a3v1 (previous name: 
Oat-k1)  and  Oatp1a3v2  (previous  name:  Oat-k2)  are  specifically  expressed  in  the  rat.  Oatp1a1 
(previous  name:  oatp1),  Oatp1a5  (previous  name:  oatp3),  Oatp1a6  (previous  name:  oatp5),  and 
Oatp4c1 are expressed in rodent kidneys. Orthologs of these isoforms, except of OATP4C1, are absent 
in humans. Because of the above-mentioned remarkable species differences in OATP, it is difficult to 
assign distinct physiological roles to each OATP in the kidneys. Several important substances, which 
are  mainly  excreted  via  the  kidneys,  are  preferable  substrates  for  the  OATP  family.  Recently, 
OATP4C1 has been revealed to be a digoxin transporter [46]. OATP4C1 is expressed exclusively in 
the  basolateral  membrane  of  proximal  tubular  cells  and  mediates  the  high-affinity  transport  of  
digoxin  (Km:  7.8  µ M)  and  ouabain  (Km:  0.38  µ M),  as  well  as  thyroid  hormones,  such  as 
triiodothyronine (Km: 5.9 µ M).  
3.3. Type I Sodium/Phosphate Transporter (NPT) Family SLC17 
Molecular studies have revealed that type I phosphate transporters (SLC17), a family of proteins 
initially characterized as phosphate carriers, are expressed at the apical membrane of renal proximal 
tubular cells. They mediate the transport of organic anions [47].
 Mouse and human NPT1 were shown 
to mediate the transport of various organic anions in a chloride-dependent manner. Moreover, because 
human NPT1 exhibits an affinity for PAH, which corresponds to the results of previous studies using  
brush-border  membrane  vesicles,  NPT1  has  also  been  suggested  to  represent  a  classical  
voltage-dependent PAH transporter. However, the influence of membrane potential on PAH transport 
was not demonstrated [48].  
Recently, we have found that the SLC17 family member, NPT4, mediates the transport of PAH in a 
voltage-sensitive manner, indicating that NPT4 may be involved in the apical drug efflux pathway [49]. 
3.4. Oligopeptide Transporter (PEPT) Family SLC15 
Peptide transporters are involved in the electrogenic, H
+-dependent transport of small peptides. 
They are also involved in the transport of various peptide-like drugs, such as β-lactam antibiotics, 
angiotensin-converting enzyme (ACE) inhibitors, and anticancer drugs [50]. Two peptide transporters, 
designated as PEPT1 and PEPT2, have been cloned. PEPT1, a low-affinity/high-capacity transporter, 
was first cloned from the rabbit intestine, and subsequently, from the rat and human intestines. Rat 
Pept1 is localized to the apical side of intestinal epithelial cells and in early regions (S1 segments) of 
the  apical  proximal  tubules.  PEPT2,  a  high-affinity/low-capacity  transporter,  appears  to  have  a 
different tissue localization than that of PEPT1. PEPT2 is highly expressed in the kidney, but not in the 
intestine.  Rat  Pept2  is  localized  to  the  apical  side  of  the  proximal  tubule  in  more  distal  regions  
(S3 segments). Toxins 2010, 2                            
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3.5. Multidrug Resistance-Associated Protein (MRP) Family ABCC 
The MRP family consists of primarily active transporters with ATP-binding cassette motifs. The 
prototype of this family is P-gp [51], which extrudes various hydrophobic molecules. P-gp particularly 
extrudes  antineoplastic compounds, such  as  vincristine, vinblastine,  adriamycin,  and  daunorubicin.  
P-gp  confers  multidrug  resistance  upon  cancer  cells  [52].  MRP1  and  MRP2  were  isolated  from 
multidrug resistant cancer cells that did not express P-gp. In addition to antineoplastic drugs, MRP2 
transports glucronides and cysteine conjugates. MRP2 is expressed in the canalicular membrane of  
hepatocytes [53]. To date, many isoforms have been identified in the MRP family. Several of these 
isoforms are expressed in the apical membrane of proximal tubular cells. MRP members in proximal 
tubular  cells  supposedly  function  as  extrusion  pumps  for  organic  anions,  especially  for  large  and 
hydrophobic organic anions, from the apical membrane. Regarding the family’s renal physiology and 
pharmacology, particular attention should be paid to two isoforms, namely, MRP2 and MRP4. MRP2 
has been shown to transport PAH, but its affinity for PAH is low (Km: 2 mM). In contrast, human 
MRP4, which is also localized in the apical membrane of proximal tubular cells, transports PAH with a 
much higher affinity (Km: 160 µ M) than that of MRP2. Furthermore, real-time PCR and Western blot 
analysis have shown that the renal cortical expression of MRP4 is approximately five-fold higher than 
that of MRP2 [54]. These data demonstrate that MRP4 plays a certain role in the efflux of PAH and 
several small hydrophilic organic anions, such as urate, cAMP, and cGMP, into the tubular lumen [55]. 
3.6. Breast Caner Resistance-Associated Protein (BCRP) ABCG2 
BCRP, a member of the ABC transporter family to which MRP4 belongs, was recently reported to 
transport uric acid [56]. In addition, the finding that the Q141K polymorphism associated with gout 
leads to decreased urate excretion capacity suggests that ABCG2 contributes to urate excretion at the 
apical membrane of renal proximal tubules or at the luminal membrane of the intestine [56], or both. 
4. OTA Transport Properties in Cloned Organic Anion Transporters 
4.1. Basolateral OATs 
Tsuda et al. [57] investigated the transport of OTA by rat kidney-specific organic anion transporter 1 
(rOat1). When expressed in Xenopus oocytes, rOat1 mediated the sodium-independent uptake of OTA 
(Km: 2.1 µM). Piroxicam, which has been shown to prevent the nephrotoxicity of OTA, inhibited 
rOat1-mediated uptake of OTA. The research group investigated the transport of OTA and OTA’s 
effect  on  cell  proliferation  and  viability  by  using  cells  derived  from  the  mouse  kidney  terminal 
proximal  tubule  (S3)  that  were  transfected  with  rOat1  cDNA  (S3  rOat1).  S3  rOat1  mediated  the 
saturable  transport  of  OTA  (Km:  0.57  µ M).  Proliferation  of  S3  rOat1  cells  was  suppressed  when 
exposed to OTA (2 and 10 µ M). This suppression was rescued by the addition of PAH (1 mM) to  
the  media.  These  results  indicated  that  OTA  is  transported  by  rOat1  and  that  the  accumulation  
of  OTA  via  rOat1  in  proximal  tubular  cells  is  the  primary  event  in  the  development  of  
OTA-induced nephrotoxicity. 
Jung  et  al.  [58]  then  investigated  the  characteristics  of  OTA  transport  by  multispecific  human 
organic anion transporters (hOAT1 and hOAT3, respectively) using cells from the second segment of Toxins 2010, 2                            
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the proximal tubule (S2) from mice that stably expressed hOAT1 and hOAT3 (S2 hOAT1 and S2 
hOAT3).  S2  hOAT1  and  S2  hOAT3  exhibited  a  time-  and  concentration-dependent  uptake  of 
[
3H]OTA (Km: 0.42 µM for hOAT1, 0.75 µ M for hOAT3). PAH, probenecid, piroxicam, octanoate, 
and  citrinin  inhibited  [
3H]OTA  uptake  by  hOAT1  and  hOAT3  in  a  competitive  manner  
(Ki:  4.29-3080  µ M),  with  different  orders  of  potency  for  hOAT1  and  for  hOAT3.  These  results 
indicate that hOAT1and hOAT3 both mediate the high-affinity transport of OTA on the basolateral 
side of the proximal tubule. Additionally, the results show that hOAT1-mediated and hOAT3-mediated 
OTA transport differs in how they are influenced by the substrates of OATs. These pharmacological 
characteristics of hOAT1 and hOAT3 may be significantly related to the development of OTA-induced 
nephrotoxicity in the human kidney. 
Zhang et al. [59] compared the characteristics of several cloned rabbit organic ion transporters 
expressed  in  cultured  cells  with  their  behavior  in  intact  rabbit  renal  proximal  tubules  (RPT)  to 
determine the contribution of each to the basolateral uptake of OTA. The activity of organic anion 
transporters OAT1 and OAT3 proved to be distinguishable because OAT1 had a high affinity for PAH 
(K t of 20 µ M), and did not support estrone sulfate (ES) transport, whereas OAT3 had a high affinity 
for  ES  (Kt  of  4.5  µ M),  and  had  a  weak  interaction  with  PAH  (IC50  >  1  mM).  In  contrast,  both 
transporters robustly accumulated OTA. Intact RPT also accumulated OTA, with OAT1 and OAT3 
each being responsible for approximately 50%; ES and PAH each reduced uptake by approximately 
50%,  and  the  combination of the two eliminated mediated  OTA uptake.  They concluded  that the 
fractional contribution of different organic ion transporters to renal secretion is influenced by their 
affinity for substrate and by their relative expression level in RPT. 
4.2. Apical OATs 
Babu et al., using mouse proximal tubule cells stably transfected with OAT4 (S2 OAT4) [60], 
examined the characteristics of OTA transport by OAT4. Immunohistochemical analysis revealed that 
the  OAT4  protein  was  localized  to  the  apical  side  of  the  proximal  tubule.  S2  OAT4  exhibited  a  
time- and concentration-dependent increase in OTA uptake (Km: 22.9 µ M). OAT4-mediated OTA 
uptake was inhibited by several substrates for OATs. Probenecid, piroxicam, octanoate, and citrinin 
inhibited OTA uptake by OAT4 in a competitive manner (Ki: 44.4–336.4 µ M). The addition of OTA 
resulted in a slight decrease in the viability of S2 OAT4 when compared with the mock. These results 
indicate that hOAT4 mediates the high-affinity transport of OTA on the apical side of the proximal 
tubule. Considering the driving force of OAT4, as indicated by Ekaratanawong et al. [61], OAT4 
seems to function as a reabsorption pathway for OTA at the apical membrane of renal proximal tubules. 
Recently,  we  have  identified  an  orphan  transporter,  NPT4  (SLC17A3),  as  a  novel  human  
voltage-driven organic anion transporter at the apical side of proximal tubules. We characterized its 
multispecific transport properties for organic anions, including PAH and several diuretics [49]. We 
also examined whether or not NPT4 mediates OTA transport by using Xenopus oocytes expressing 
hNPT4 [62]. hNPT4 demonstrated time- and concentration-dependent uptake of OTA. Like in the 
transport of PAH, OTA uptake by hNPT4 was enhanced in the medium with replacement of K
+ by Na
+. 
This suggests voltage-driven transport of OTA by hNPT4. hNPT4-mediated OTA uptake was inhibited 
by several organic anions, such as probenecid and piroxicam. These results indicate that hNPT4 is an Toxins 2010, 2                            
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apical efflux pathway for OTA entering via basolateral OAT1 or OAT3 (or both) in renal proximal  
tubules (Figure 3). 
Figure  3.  OTA  secretion  in  proximal  tubular  cells  in  humans.  Organic 
anion/dicarboxylates (DCs) exchangers OAT1 and OAT3 function as entrance pathways 
for OTA, and NPT4 and MRP2 may be its exit route in proximal tubular cells. OAT4 at the 
apical  membrane  may  function  as  a  reabsorptive  pathway  for  OTA.  When  probenecid 
(inhibitor of OATs) or PAH (substrate for both OAT1 and OAT3) is coadministered with 
OTA, they inhibit the tubular secretion of OTA, thus reducing its potential risk. 
 
4.3. OATPs 
Takeuchi et al. characterized the interactions of various compounds with kidney-specific organic 
anion transporters Oat-k1 and Oat-k2 [63]. By using MDCK cells stably transfected with Oat-k1 or 
Oat-k2 cDNA, the antitumor drug methotrexate, OTA, endogenous organic anions (thyroid hormones, 
taurocholic acid, and conjugated steroids), and the antiretroviral drug zidovudine were shown to be 
substrates  for  these  transporters.  These  results  suggested  that  Oat-k1  and  Oat-k2  could  serve  as 
multispecific  transporters,  mediating  the  transport  of  a  wide  variety  of  endogenous  substances, 
xenobiotics,  and  their  metabolites  in  the  kidney,  presumably  via  several  interaction  sites  in  
their molecules. 
4.4. MRP2 
The  ATP-dependent  membrane  transporters,  P-glycoprotein  (P-gp),  MRP2,  and  BCRP,  are 
localized  in  the  luminal  membranes  of  the  intestines  and  liver,  as  well  as  in  the  kidney.  They 
counteract absorption and increase excretion of xenobiotics and drugs. Leier et al. investigated the 
transport function of renal apical multidrug resistance protein MRP2 (ABCC2) using PAH and OTA as 
transport substrates [64]. Membrane vesicles from HEK-MRP2 cells containing recombinant human 
MRP2 and from control vector-transfected HEK-Co cells were incubated with various concentrations 
of [
3H]PAH and [
3H]OTA. The net ATP-dependent transport into inside-out vesicles was determined Toxins 2010, 2                            
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(Km for PAH: 880 µ M). OTA inhibited MRP2-mediated PAH transport (IC50: 58 µ M). OTA was itself 
a substrate for MRP2.  
Schrickx et al. [65] investigated the absorption and secretion of OTA in a Caco-2 cell model.  
Caco-2 cells secreted OTA to the luminal side in a concentration-dependent manner. This secretory 
permeability was higher than the absorptive permeability, while the absorptive permeability remained 
constant for all OTA concentrations tested. The secretion decreased and absorption increased in the 
presence  of  the  MRP-inhibitor  MK571,  the  P-gp  and  BCRP  inhibitor  GF120918,  and  the  
BCRP-inhibitor  Ko143,  suggesting  that  the  secretion  of  OTA  is  mediated  by  MRP2  and  BCRP. 
Cyclosporine A also decreased the secretory permeability, but did not affect absorptive permeability. 
PSC833 changed neither the absorption nor the secretion of OTA. Hence, it can be suggested that OTA 
is a substrate for MRP2 as well as for BCRP. These findings are of interest for evaluating mycotoxin 
absorption after oral ingestion, tissue distribution, and particularly, mycotoxin excretion pathways, 
including renal, biliary, and mammary gland excretion. 
5. Transport of OTA in Extrarenal Tissues 
5.1. Intestine 
OTA is absorbed from the small intestine and binds to serum albumin in plasma. The prolonged  
half-life of OTA results from its reabsorption by the proximal tubules and via enterohepatic circulation. 
Berger et al. [66] investigated the mechanism by which OTA crosses the intestine. They used a cell 
culture system consisting of Caco-2 cells as an in vitro model of the human intestinal epithelium. 
Cytotoxicity assays on proliferating Caco-2 cells showed that OTA (0.4 µ M) inhibits MTT reduction 
by 50%. Transepithelial transport and intracellular accumulation of OTA were studied in Caco-2 cells 
and  were  differentiated  in  bicameral  inserts.  At  pH  7.4,  OTA  is  transported  preferentially  in  the 
basolateral (BL) to apical (A) direction, suggesting a net secretion. Conditions closer to the in vivo 
situation  in  the  duodenum  (A:  pH  6.0,  BL:  pH  7.4)  increased  intracellular  accumulation  and 
transepithelial transport. A to BL transport becomes higher than BL to A transport, suggesting OTA 
absorption.  Addition  of  serum  albumin  in  the  BL  compartment  further  increases  OTA  absorption 
across Caco-2 cells and suggests that in vivo OTA transport from the serosal to the luminal side of 
enterocytes is prevented, due to its binding to plasma proteins. A and BL transport and intracellular 
accumulation of OTA are increased in the presence of non-specific inhibitors of MRPs (indomethacin, 
genistein, and probenecid) and in the presence of 1-chloro-2,4-dinitrobenzene (biotransformed into 
2,4-dinitrophenyl-glutathione, a specific inhibitor of MRPs), but are not affected by verapamil, an 
inhibitor of P-gp. This suggests that MRP2 might be involved in transepithelial transport. Therefore, 
absorption of OTA across the intestinal mucosa would be limited, due to its excretion through MRP2 
at the apical pole of enterocytes. 
In addition, as mentioned in section 3.5, ABC transporters, such as P-gp, MRP2, and BCRP, which 
are localized in the luminal membranes of the intestine, counteract absorption and increase excretion 
of xenobiotics and drugs. Schrickx et al. [65] suggested that OTA is a substrate for MRP2 as well  
as for BCRP. Toxins 2010, 2                            
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5.2. Liver 
Upon intestinal absorption, a large part of OTA is taken up by hepatocytes and eliminated into bile. 
Kontaxi et al. [67] characterized hepatocellular uptake of [
3H]OTA in isolated rat hepatocytes. A 
saturable (Km: 18.9 µ M) and energy-dependent OTA transport was found. This uptake was inhibited 
by various bile acids, sulfobromophthalein (BSP), and the thrombin inhibitor CRC 220. Because all 
inhibitors are substrates of the organic anion-transporting polypeptide (oatp), a hepatic carrier [44], 
uptake experiments were performed in oatp cRNA-injected Xenopus oocytes. These studies revealed 
an oatp-specific OTA uptake (Km: 16.6 µ M). Known oatp substrates cis-inhibited OTA uptake in oatp 
cRNA-injected oocytes in close correlation with the results obtained from isolated hepatocytes. These 
results  reveal  OTA  as  a  substrate  for  oatp.  They  further  support  the  multispecific  nature  of  
oatp-mediated transport and stress the importance of this carrier for hepatic clearance of xenobiotics. 
As mentioned before, Schrickx et al. [65] suggested that OTA is a substrate for MRP2 and BCRP, 
which are localized in the canalicular membranes of the liver. 
5.3. Blood-brain Barrier 
Ose et al. [68] investigated the role of a multispecific organic anion transporter, Oatp1a4/Slco1a4, 
in  drug  transport  across  the  blood-brain  barrier.  In  vitro  transport  studies  using  HEK293  cells 
expressing  mouse  Oatp1a4  revealed  the  following  compounds  as  Oatp1a4  substrates:  pitavastatin  
(Km: 8.3 µM), rosuvastatin (Km: 12 µ M), pravastatin, taurocholate (Km: 40 µ M), digoxin, and OTA. 
Double  immunohistochemical  staining  of  Oatp1a4  with  P-gp  or  glial  fibrillary  acidic  protein 
demonstrated that Oatp1a4 signals partly colocalized with P-gp signals, but not with glial fibrillary 
acidic protein, suggesting that Oatp1a4 is expressed in both the luminal and the abluminal membranes 
of mouse brain capillary endothelial cells. The brain-to-blood transport of pitavastatin, rosuvastatin, 
pravastatin, and taurocholate after microinjection into the cerebral cortex was significantly decreased 
in  Oatp1a4(−/−)  mice,  compared  with  that  in  wild-type  mice.  The  blood-to-brain  transport  of 
pitavastatin,  rosuvastatin,  taurocholate,  and  OTA,  determined  by  in  situ  brain  perfusion,  was 
significantly lower in Oatp1a4(−/−) mice than in wild-type mice. 
6. OTA as a Regulator of Transporter Expression 
In rodents, OTA intoxication impairs various proximal tubule functions, including secretion of PAH, 
possibly via affecting the renal organic anion transporters (Oat). However, an effect of OTA on the 
activity/expression of specific Oats in the mammalian kidney has not been reported. Zlender et al. 
studied tubular integrity by microscopy, abundance of basolateral (rOat1, rOat3) and brush-border 
(rOat2,  rOat5)  rOat  proteins  by  immunochemical  methods,  and  expression  of  rOats  mRNA  by  
RT-PCR in kidneys from male rats gavaged with various doses of OTA every second day for 10 days 
[69].  The  OTA  treatment  caused  (1)  dose-dependent  damage  of  the  cells  in  the  S3  segments  of 
medullary rays; (2) a dual effect upon rOats in the proximal tubules with low doses upregulating the 
abundance of all rOats and high doses downregulating the abundance of rOat1, and (3) unchanged 
mRNA expression for all rOats at low OTA doses, and downregulation of rOats at high OTA doses. 
Changes in the expression of renal Oats were associated with enhanced OTA accumulation in tissue Toxins 2010, 2                            
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and  excretion  in  urine,  whereas  the  indicators  of  oxidative  stress  either  remained  unchanged 
(malondialdehyde, glutathione, 8-hydroxydeoxyguanosine) or became deranged (microtubules). While 
OTA  accumulation  and  downregulation  of  rOats  in  the  kidney  are  consistent  with  the  previously 
reported  impaired  renal  PAH  secretion  in  rodents  intoxicated  with  high  OTA  doses,  the  
post-transcriptional upregulation of Oats at low OTA doses may contribute to OTA accumulation and 
development of nephrotoxicity. 
7. Conclusion 
Renal  organic  anion  transporters  function  as  an  entrance  pathway  for  several  xenobiotics  and 
contribute to their accumulation in proximal tubular cells. In this review, we showed that nephrotoxic 
compounds, such as OTA, are substrates for renal drug transporters by transporter-stably expressing 
cell  lines  [57,58,60].  Use  of  transporter-stably  expressing  cells  (S2  OATs),  together  with  
non-expressing  cells  (S2  mock),  is  helpful  for  checking  the  possibility  of  transporter-mediated 
nephrotoxicity. Thus, transporter-stably expressing cell lines seem to be useful systems as an animal 
alternative model for the screening of potential nephrotoxic compounds. 
Besides  OTA,  the  nephrotoxic  effects  of  carbapenem  antibiotics  and  antiviral  drugs,  such  as 
adefovir and cidofovir, are closely associated with OATs [70]. The nephrotoxicity of these compounds 
could be reduced by the coadministration of other substrates of OATs or of inhibitors of OATs. Indeed, 
recently, a new application of probenecid as a nephroprotectant in therapy with the antiviral drug 
cidofovir was determined [71]. When probenecid is coadministered with cidofovir, probenecid inhibits 
the tubular accumulation of cidofovir, leading to the reduction of its potential risk. Thus, blockade of 
transport by competitors eliminates or reduces the nephrotoxic response. 
An understanding of the molecular mechanism of renal organic transport is essential to achieving 
desired therapeutic outcomes in response to chemical exposure and drug interactions, to understanding 
the  progression  of  some  disease  states,  and  to  predicting  the  influence  of  genetic  variation  upon  
these processes. 
Renal tubular secretion and reabsorption of OTA, presumably via the OAT system, may play an 
important role in OTA accumulation and development of nephrotoxicity. Neverthess it should be kept 
in mind that albumin binding impacts transport in vitro and thus must be considered when thinking 
about the clearance of OTA in vivo [72]. Thus, a molecular understanding of renal OTA transport will 
lead to the development of possible strategies for the prevention of OTA-induced nephrotoxicity. 
Acknowledgement 
This work was supported in part by grants from the Japan Society for the Promotion of Science 
(KAKENHI  21390073,  21659216,  21890245),  the  Nakatomi  Foundation,  and  Gout  Research 
Foundation of Japan. 
References 
1.  van der Merwe, K.J.; Steyn, P.S.; Fourie, L.; Scott, D.B.; Theron, J.J. Ochratoxin A, a toxic 
metabolite produced by Aspergillus ochraceus Wilh. Nature 1965, 205, 1112–1113.  Toxins 2010, 2                            
 
 
1394 
2.  Harwig, J.; Kuiper-Goodmann, T.; Scott, P.M.; Rechcigl, M. In Handbook of Foodborne Diseases 
of Biological Origin; CRC Press: Boca Raton, FL, USA, 1983; pp. 193–238. 
3.  Krogh, P.; Hald, B.; Pedersen, E.J. Occurrence of ochratoxin A and citrinin in cereals associated 
with mycotoxic porcine nephropathy. Acta Pathol. Microbio. Scand. Sect. B 1973, 81, 689–695. 
4.  WHO.  Selected  mycotoxins:  Ochratoxins,  trichothecenes, and ergot.  In Environmental Health 
Criteria; World Health Organization: Geneva, Switzerland, 1990; p. 105. 
5.  Dietrich, D.R.; Heussner, A.H.; O'Brien, E. Ochratoxin A: Comparative pharmacokinetics and 
toxicological implications (experimental and domestic animals and humans). Food Addit. Contam. 
2005, 22 (Suppl. 1), 45–52. 
6.  Clark, H.A.; Snedeker, S.M. Ochratoxin A: Its cancer risk and potential for exposure. J. Toxicol. 
Environ. Health B. Crit. Rev. 2006, 9, 265–296. 
7.  Manderville, R.A.; Pfohl-Leszkowicz, A. Bioactivation and DNA adduction as a rationale for 
ochratoxin A carcinogenesis. World Mycotoxin J. 2008, 1, 357–367. 
8.  Kuiper-Goodman,  T.;  Scott,  P.M.  Risk  assessment  of  the  mycotoxin  ochratoxin  A.  Biomed. 
Environ. Sci. 1989, 2, 179–248.  
9.  Pfohl-Leszkowicz,  A.;  Manderville,  R.A.  Ochratoxin  A:  An  overview  on  toxicity  and 
carcinogenicity in animals and humans. Mol. Nutr. Food Res. 2007, 51, 61–99. 
10.  Simon, P. Ochratoxin and kidney disease in the human. J. Toxicol. 1996, 15, 239–249. 
11.  Gekle, M.; Silbernagl, S. Mechanism of ochratoxin A-induced reduction of glomerular filtration 
rate in rats. J. Pharmacol. Exp. Ther. 1993, 267, 316–321. 
12.  Gekle, M.; Silbernagl, S. The role of the proximal tubule in ochratoxin A nephrotoxicity in vivo: 
Toxicodynamic and toxokinetic aspects. Renal Physiol. Biochem. 1994, 17, 40–49. 
13.  Dahlmann,  A.;  Dantzler,  W.H.;  Silbernagl,  S.;  Gekle,  M.  Detailed  mapping  of  ochratoxin  A 
reabsorption along the rat nephron in vivo: The nephrotoxin can be reabsorbed in all nephron 
segments by different mechanisms. J. Pharmacol. Exp. Ther. 1998, 286, 157–162. 
14.  Stein, A.F.; Phillips, T.D.; Kubena, L.F.; Harvey, R.B. Renal tubular secretion and reabsorption as 
factors in ochratoxicosis: Effects of probenecid on nephrotoxicity. J. Toxicol. Environ. Health 
1985, 16, 593–605. 
15.  Stojković, R.; Hult, K.; Gamulin, S.; Plestina R. High affinity binding of ochratoxin A to plasma 
constituents. Biochem. Int. 1984, 9, 33–38. 
16.  Hagelberg,  S.;  Hult,  K.;  Fuchs,  R.  Toxicokinetics  of  ochratoxin  A  in  several  species  and  its 
plasma-binding properties. J. Appl. Toxicol. 1989, 9, 91–96. 
17.  Gekle,  M.;  Sauvant,  C.;  Schwerdt,  G.  Ochratoxin  A  at  nanomolar  concentrations:  A  signal 
modulator in renal cells. Mol. Nutr. Food Res. 2005, 49, 118–130. 
18.  Berndt, W.O.; Hayes, A.W. In vivo and in vitro changes in renal function caused by ochratoxin A 
in the rat. Toxicology 1979, 12, 5–17. 
19.  Friis, C.; Brinn, R.; Hald, B. Uptake of ochratoxin A by slices of pig kidney cortex. Toxicology 
1988, 52, 209–217. 
20.  Sokol,  P.P.;  Ripich,  G.;  Holohan,  P.D.;  Ross,  C.R.  Mechanism  of  ochratoxin  A  transport  in 
kidney. J. Pharmacol. Exp. Ther. 1988, 246, 460–465. 
21.  Zingerle, M.; Silbernagl, S.; Gekle M. Reabsorption of the nephrotoxin ochratoxin A along the rat 
nephron in vivo. J. Pharmacol. Exp. Ther. 1997, 280, 220–224. Toxins 2010, 2                            
 
 
1395 
22.  Groves, C.E.; Morales, M.; Wright, S.H. Peritubular transport of ochratoxin A in rabbit renal 
proximal tubules. J. Pharmacol. Exp. Ther. 1998, 284, 943–948. 
23.  Groves, C.E.; Nowak, G.; Morales, M. Ochratoxin A secretion in primary cultures of rabbit renal 
proximal tubule cells. J. Am. Soc. Nephrol. 1999, 10, 13–20. 
24.  Schwerdt, G.; Gekle, M.; Freudinger, R.; Mildenberger, S.; Silbernagl, S. Apical-to-basolateral 
transepithelial transport of Ochratoxin A by two subtypes of Madin-Darby canine kidney cells. 
Biochim. Biophys. Acta 1997, 1324, 191–199. 
25.  Schwerdt, G.; Freudinger, R.; Silbernagl, S.; Gekle, M. Apical uptake of radiolabelled ochratoxin 
A into Madin-Darby canine kidney cells. Toxicology 1998, 131, 193–202. 
26.  Bahnemann, E.;  Kerling, H.P.;  Ensminger,  S.;  Schwerdt, G.; Silbernagl,  S.;  Gekle,  M.  Renal 
transepithelial secretion of ochratoxin A in the non-filtering toad kidney. Toxicology 1997, 120, 
11–17. 
27.  Sauvant, C.; Silbernagl, S.; Gekle, M. Exposure to ochratoxin A impairs organic anion transport 
in proximal-tubule-derived opossum kidney cells. J. Pharmacol. Exp. Ther. 1998, 287, 13–20. 
28.  Welborn, J.R.; Groves, C.E.; Wright, S.H. Peritubular transport of ochratoxin A by single rabbit 
renal proximal tubules. J. Am. Soc. Nephrol. 1998, 9, 1973–1982. 
29.  Burckhardt, B.C.; Burckhardt, G. Transport of organic anions across the basolateral membrane of 
proximal tubule cells. Rev. Physiol. Biochem. Pharmacol. 2003, 146, 95–158. 
30.  Wright, S.H.; Dantzler, W.H. Molecular and cellular physiology of renal organic cation and anion 
transport. Physiol. Rev. 2004, 84, 987–1049. 
31.  Anzai,  N.;  Kanai,  Y.;  Endou,  H.  Organic  anion  transporter  family:  Current  knowledge.  
J. Pharmacol. Sci. 2006, 100, 411–426. 
32.  Anzai,  N.;  Endou,  H.  Drug  Transport  in  the  Kidney.  In  Drug  Transporters  Molecular 
Characterization and Role in Drug Disposition; You, G., Morris, M.E., Eds.; John Wiley & Sons, 
Inc.: Hoboken, NJ, USA, 2007; pp. 463–493. 
33.  Srimaroeng, C.; Perry, J.L.; Pritchard, J.B. Physiology, structure, and regulation of the cloned 
organic anion transporters. Xenobiotica 2008, 38, 889–935. 
34.  Ahn, S.Y.; Bhatnagar, V. Update on the molecular physiology of organic anion transporters. Curr. 
Opin. Nephrol. Hypertens. 2008, 17, 499–505. 
35.  Sekine,  T.;  Watanabe,  N.;  Hosoyamada,  M.;  Kanai,  Y.;  Endou,  H.  Expression  cloning  and 
characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 1997, 272, 
18526–18529. 
36.  Sekine,  T.;  Cha,  S.H.;  Endou,  H.  The  multispecific  organic  anion  transporter  (OAT)  family. 
Pflugers Arch. 2000, 440, 337–350. 
37.  Sekine,  T.;  Cha,  S.H.;  Tsuda,  M.;  Apiwattanakul,  N.;  Nakajima,  N.;  Kanai,  Y.;  Endou,  H. 
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. 
FEBS Lett. 1998, 429, 179–182. 
38.  Kusuhara, H.; Sekine, T.; Utsunomiya-Tate, N.; Tsuda, M.; Kojima, R.; Cha, S.H.; Sugiyama, Y.; 
Kanai, Y.; Endou, H. Molecular cloning and characterization of a new multispecific organic anion 
transporter from rat brain. J. Biol. Chem. 1999, 274, 13675–13680. Toxins 2010, 2                            
 
 
1396 
39.  Cha, S.H.; Sekine, T.; Kusuhara, H.; Yu, E.; Kim, J.Y.; Kim, D.K.; Sugiyama, Y.; Kanai, Y.; 
Endou, H. Molecular cloning and characterization of multispecific organic anion transporter 4 
expressed in the placenta. J. Biol. Chem. 2000, 275, 4507–4512. 
40.  Anzai, N.; Jutabha, P.; Enomoto, A.; Yokoyama, H.; Nonoguchi, H.; Hirata, T.; Shiraya, K.; He, 
X.; Cha, S.H.; Takeda, M.; Miyazaki, H.; Sakata, T.; Tomita, K.; Igarashi, T.; Kanai, Y.; Endou, 
H.  Functional  characterization  of  rat  organic  anion  transporter  5(Slc22a19)  at  the  apical 
membrane of renal proximal tubules. J. Pharmacol. Exp. Ther. 2005, 315, 534–544. 
41.  Yokoyama, H.; Anzai, N.; Ljubojevic, M.; Ohtsu, N.; Sakata, T.; Miyazaki, H.; Nonoguchi, H.; 
Islam, R.; Onozato,  M.;  Tojo,  A.; Tomita,  K.; Kanai, Y.; Igarashi,  T.; Sabolic, I.; Endou H. 
Functional  and  immunochemical  characterization  of  a  novel  organic  anion  transporter  Oat8 
(Slc22a9) in rat renal collecting duct. Cell. Physiol. Biochem. 2008, 21, 269–278. 
42.  Tsuchida, H.; Anzai, N.; Shin, H.J.; Wempe, M.F.; Jutabha, P.; Enomoto, A.; Cha, S.H.; Satoh, 
T.;  Ishida,  M.;  Sakurai,  H.;  Endou,  H.  Identification  of  a  novel  organic  anion  transporter 
mediating  carnitine  transport  in  mouse  liver  and  kidney.  Cell.  Physiol.  Biochem.  2010,  25,  
511–522. 
43.  Bahn, A.; Hagos, Y.; Reuter, S.; Balen, D.; Brzica, H.; Krick, W.; Burckhardt, B.C.; Sabolic, I.; 
Burckhardt, G. Identification of a new urate and high affinity nicotinate transporter, hOAT10 
(SLC22A13). J. Biol. Chem. 2008, 283, 16332–16241. 
44.  Jacquemin, E.; Hagenbuch, B.; Stieger, B.; Wolkoff, A.W.; Meier, P.J. Expression cloning of a rat 
liver Na
+-independent organic anion transporter. Proc. Natl. Acad. Sci. USA 1994, 91, 133–137. 
45.  Hagenbuch, B.; Meier, P.J. Organic anion transporting polypeptides of the OATP/ SLC21 family: 
Phylogenetic  classification  as  OATP/  SLCO  superfamily,  new  nomenclature  and 
molecular/functional properties. Pfluegers Arch. 2004, 447, 653–665. 
46.  Mikkaichi, T.; Suzuki, T.; Onogawa, T.; Tanemoto, M.; Mizutamari, H.; Okada, M.; Chaki, T.; 
Masuda, S.; Tokui, T.; Eto, N.; Abe, M.; Satoh, F.; Unno, M.; Hishinuma, T.; Inui, K.; Ito, S.; 
Goto, J.; Abe, T. Isolation and characterization of a digoxin transporter and its rat homologue 
expressed in the kidney. Proc. Natl. Acad. Sci. USA 2004, 101, 3569–3574. 
47.  Reimer, R.J.; Edwards, R.H. Organic anion transport is the primary function of the SLC17/type I 
phosphate transporter family. Pfluegers Arch. 2004, 447, 629–635. 
48.  Uchino,  H.;  Tamai,  I.;  Yamashita,  K.;  Minemoto,  Y.;  Sai,  Y.;  Yabuuchi,  H.;  Miyamoto,  K.; 
Takeda,  E.;  Tsuji,  A.  p-aminohippuric  acid  transport  at  renal  apical  membrane  mediated  by 
human  inorganic  phosphate  transporter  NPT1.  Biochem.  Biophys.  Res.  Commun.  2000,  270,  
254–259. 
49.  Jutabha,  P.;  Anzai,  N.;  Kitamura,  K.;  Taniguchi,  A.;  Kaneko,  S.;  Yamada,  H.;  Shimada,  H.; 
Uchimura, K.; Hayata, M.; Morinaga, J.; Urano, W.; Seki, G.; Uchida, S.; Endou, H.; Sakurai, H. 
Mutations in renal drug efflux transporter hOATv1 cause hyperuricemia. Endocrine J. 2010, 57 
(Suppl. 2), S563. 
50.  Terada, T.; Inui, K. Peptide transporters: structure, function, regulation and application for drug 
delivery. Curr. Drug Metab. 2004, 5, 85–94. 
51.  Ford,  J.M.;  Hait,  W.N.  Pharmacology  of  drugs  that  alter  multidrug  resistance  in  cancer. 
Pharmacol. Rev. 1990, 42, 155–199. Toxins 2010, 2                            
 
 
1397 
52.  Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent 
transporters. Nat. Rev. Cancer. 2002, 2, 48–58. 
53.  Russel, F.G.; Masereeuw, R.; van Aubel, R.A. Molecular aspects of renal anionic drug transport. 
Annu. Rev. Physiol. 2002, 64, 563–594. 
54.  Smeets, P.H.; van Aubel, R.A.; Wouterse, A.C.; van den Heuvel, J.J.; Russel, F.G. Contribution 
of  multidrug resistance protein  2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate 
(PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. 
2004, 15, 2828–2835. 
55.  van  Aubel,  R.A.;  Smeets,  P.H.;  van  den  Heuvel,  J.J.;  Russel,  F.G.  Human  organic  anion 
transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple 
allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. 2005, 288, F327–F333. 
56.  Ishikawa,  T.;  Nakagawa,  H.  Human  ABC  transporter  ABCG2  in  cancer  chemotherapy  and 
pharmacogenomics. J. Exp. Ther. Oncol. 2009, 8, 5–24. 
57.  Tsuda, M.; Sekine, T.; Takeda, M.; Cha, S.H.; Kanai, Y.; Kimura, M.; Endou, H. Transport of 
ochratoxin A by renal multispecific organic anion transporter 1. J. Pharmacol. Exp. Ther. 1999, 
289, 1301–1305. 
58.  Jung,  K.Y.;  Takeda,  M.;  Kim,  D.K.;  Tojo,  A.;  Narikawa,  S.;  Yoo,  B.S.;  Hosoyamada,  M.;  
Cha, S.H.; Sekine, T.; Endou, H. Characterization of ochratoxin A transport by human organic 
anion transporters. Life Sci. 2001, 69, 2123–2135. 
59.  Zhang, X.; Groves, C.E.; Bahn, A.; Barendt, W.M.; Prado, M.D.; Rö diger, M.; Chatsudthipong, 
V.; Burckhardt, G.; Wright, S.H. Relative contribution of OAT and OCT transporters to organic 
electrolyte  transport  in  rabbit  proximal  tubule.  Am.  J.  Physiol.  Renal  Physiol.  2004,  287,  
F999–F1010. 
60.  Babu, E.; Takeda, M.; Narikawa, S.; Kobayashi, Y.; Enomoto, A.; Tojo, A.; Cha, S.H.; Sekine, 
T.; Sakthisekaran, D.; Endou, H. Role of human organic anion transporter 4 in the transport of 
ochratoxin A. Biochim. Biophys. Acta 2002, 1590, 64–75. 
61.  Ekaratanawong, S.; Anzai, N.; Jutabha, P.; Miyazaki, H.; Noshiro, R.; Takeda, M.; Kanai, Y.; 
Sophasan,  S.;  Endou,  H.  Human  organic  anion  transporter  4  is  a  renal  apical  organic 
anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol. Sci. 2004, 94, 297–304. 
62.  Jutabha,  P.;  Anzai,  N.;  Thammapratip,  T.;  Endou,  H.;  Sakurai,  H.  Ochratoxin  A  transport 
mediated by a novel human voltage-driven organic anion transporter hOATv1. J. Tox. Sci. 2010, 
35 (Suppl. 1), S219. 
63.  Takeuchi,  A.;  Masuda,  S.;  Saito,  H.;  Abe,  T.;  Inui,  K.  Multispecific  substrate  recognition  of 
kidney–specific organic anion transporters OAT-K1 and OAT-K2. J. Pharmacol. Exp. Ther. 2001, 
299, 261–267. 
64.  Leier,  I.;  Hummel-Eisenbeiss,  J.;  Cui,  Y.;  Keppler,  D.  ATP-dependent  para-aminohippurate 
transport by apical multidrug resistance protein MRP2. Kidney Int. 2000, 57, 1636–1642. 
65.  Schrickx,  J.;  Lektarau,  Y.;  Fink-Gremmels,  J.  Ochratoxin  A  secretion  by  ATP-dependent 
membrane transporters in Caco-2 cells. Arch. Toxicol. 2006, 80, 243–249. 
66.  Berger, V.; Gabriel, A.F.; Sergent, T.; Trouet, A.; Larondelle, Y.; Schneider, Y.J. Interaction of 
ochratoxin  A  with  human  intestinal  Caco-2  cells:  Possible  implication  of  a  multidrug  
resistance-associated protein (MRP2). Toxicol. Lett. 2003, 140–141, 465–476. Toxins 2010, 2                            
 
 
1398 
67.  Kontaxi, M.; Echkardt, U.; Hagenbuch, B.; Stieger, B.; Meier, P.J.; Petzinger, E. Uptake of the 
mycotoxin  ochratoxin  A  in  liver  cells  occurs  via  the  cloned  organic  anion  transporting 
polypeptide. J. Pharmacol. Exp. Ther. 1996, 279, 1507–1513. 
68.  Ose,  A.;  Kusuhara,  H.;  Endo,  C.;  Tohyama,  K.;  Miyajima,  M.;  Kitamura,  S.;  Sugiyama,  Y. 
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and 
efflux of drugs across the blood-brain barrier. Drug Metab. Dispos. 2010, 38, 168–176. 
69.  Zlender, V.; Breljak, D.; Ljubojević, M.; Flajs, D.; Balen, D.; Brzica, H.; Domijan, A.M.; Peraica, 
M.; Fuchs, R.; Anzai, N.; Sabolić, I. Low doses of ochratoxin A upregulate the protein expression 
of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex.  Toxicol. Appl. 
Pharmacol. 2009, 239, 284–296. 
70.  Cihlar,  T.;  Lin,  D.C.;  Pritchard,  J.B.;  Fuller,  M.D.;  Mendel,  D.B.;  Sweet,  D.H.  The  antiviral 
nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic 
anion transporter 1. Mol. Pharmacol. 1999, 56, 570–580. 
71.  Lacy,  S.A.;  Hitchcock,  M.J.;  Lee,  W.A.;  Tellier,  P.;  Cundy,  K.C.  Effect  of  oral  probenecid 
coadministration  on  the  chronic  toxicity  and  pharmacokinetics  of  intravenous  cidofovir  in 
cynomolgus monkeys. Toxicol. Sci. 1998, 44, 97–106. 
72.  Dai,  J.;  Park,  G.;  Perry,  J.L.;  Il'ichev,  Y.V.;  Bow,  D.A.;  Pritchard,  J.B.;  Faucet,  V.;  
Pfohl-Leszkowicz, A.; Manderville, R.A.; Simon, J.D. Molecular aspects of the transport and 
toxicity of ochratoxin A. Acc. Chem. Res. 2004, 37, 874–881. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 